On May 12, 2023, the FDA held its first Advisory Committee meeting for SRP-9001, a gene therapy intended to treat Duchenne. With a favorable vote from the Advisory Committee, our Duchenne community is optimistic and ready to support the continuing progress on SRP-9001’s ongoing review through the PDUFA regulatory review date of May 29.

In this Virtual Town Hall, Duchenne community partners debrief on the meeting and provide next steps leading up to the PDUFA date.